RZLT NASDAQ
Rezolute, Inc.
1W: +3.2%
1M: -2.0%
3M: -22.4%
YTD: +76.0%
1Y: -57.6%
3Y: +302.1%
5Y: -42.6%
$4.11
+0.28 (+7.46%)
Weekly Expected Move ±10.8%
$3
$3
$4
$4
$5
Credit Risk of going bust: higher than 88% of companies Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99.9%), Rezolute, Inc. would be worth roughly what it owes.
Total debt $934K against a stock market value of $369.5M.
Distance to default 1.88 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $467K (short-term plus half of long-term), stock volatility 224.4%; Altman Z'' -4.55. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 99.9%), Rezolute, Inc. would be worth roughly what it owes.
Total debt $934K against a stock market value of $369.5M.
Distance to default 1.88 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $467K (short-term plus half of long-term), stock volatility 224.4%; Altman Z'' -4.55. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$369.5M
52W Range1.07-11.46
Volume1,543,500
Avg Volume1,664,425
Beta0.61
Dividend—
Analyst Ratings
Company Info
CEONevan Charles Elam
Employees58
SectorHealthcare
IndustryBiotechnology
IPO Date2013-01-14
Websiterezolutebio.com
275 Shoreline Drive
Redwood City, CA 94065
US
Redwood City, CA 94065
US
650 206 4507
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Latest News
Rezolute (NASDAQ:RZLT) Stock Price Crosses Below 200-Day Moving Average – What’s Next?
Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts
Rezolute upgraded at Cantor on pre-BLA meeting for ersodetug
Rezolute (NASDAQ:RZLT) Stock Sees Unusually High Call Option Buying
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Evans Daron | G-Gift | 16,000 | — | 2026-10-21 |
| Evans Daron | G-Gift | 4,000 | — | 2026-10-21 |
| Karnawat Sunil Ratil | F-InKind | 2,267 | $4.50 | 2026-09-02 |
| Elam Nevan C | F-InKind | 8,004 | $4.99 | 2026-07-02 |
| Evans Daron | F-InKind | 3,062 | $4.99 | 2026-07-02 |